Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alphavirus Infections | 2 | 2023 | 7 | 0.980 |
Why?
|
| HIV Infections | 19 | 2018 | 2586 | 0.950 |
Why?
|
| Acquired Immunodeficiency Syndrome | 12 | 2015 | 226 | 0.930 |
Why?
|
| Risk-Taking | 7 | 2015 | 457 | 0.890 |
Why?
|
| Alphavirus | 2 | 2023 | 10 | 0.840 |
Why?
|
| Aedes | 1 | 2023 | 43 | 0.770 |
Why?
|
| Adolescent Behavior | 4 | 2015 | 281 | 0.720 |
Why?
|
| Risk Reduction Behavior | 3 | 2019 | 138 | 0.680 |
Why?
|
| Bunyaviridae | 1 | 2020 | 5 | 0.650 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 749 | 0.650 |
Why?
|
| Puerto Rico | 24 | 2017 | 1413 | 0.590 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2017 | 2 | 0.540 |
Why?
|
| Enteritis | 1 | 2017 | 6 | 0.540 |
Why?
|
| Agammaglobulinemia | 1 | 2017 | 19 | 0.530 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 28 | 0.530 |
Why?
|
| Candidiasis | 1 | 2017 | 89 | 0.510 |
Why?
|
| School Health Services | 1 | 2015 | 90 | 0.440 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2013 | 129 | 0.400 |
Why?
|
| Adolescent Development | 1 | 2010 | 40 | 0.320 |
Why?
|
| Male | 32 | 2024 | 23409 | 0.310 |
Why?
|
| Humans | 37 | 2024 | 43102 | 0.300 |
Why?
|
| Female | 32 | 2024 | 24698 | 0.300 |
Why?
|
| Adolescent | 14 | 2024 | 6081 | 0.300 |
Why?
|
| Social Behavior | 1 | 2010 | 161 | 0.290 |
Why?
|
| Prospective Studies | 7 | 2021 | 1600 | 0.290 |
Why?
|
| Hepatitis C | 4 | 2013 | 139 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2013 | 989 | 0.280 |
Why?
|
| Primary Health Care | 3 | 2021 | 380 | 0.270 |
Why?
|
| Fever | 2 | 2024 | 62 | 0.260 |
Why?
|
| Middle Aged | 20 | 2024 | 12222 | 0.240 |
Why?
|
| Spain | 3 | 2021 | 44 | 0.240 |
Why?
|
| Chikungunya virus | 2 | 2022 | 18 | 0.240 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 3156 | 0.230 |
Why?
|
| Disease Outbreaks | 2 | 2023 | 175 | 0.220 |
Why?
|
| Pilot Projects | 3 | 2015 | 760 | 0.220 |
Why?
|
| Leptospirosis | 1 | 2024 | 31 | 0.210 |
Why?
|
| Eponyms | 1 | 2023 | 1 | 0.200 |
Why?
|
| Malaria | 1 | 2024 | 90 | 0.200 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 830 | 0.200 |
Why?
|
| Adult | 24 | 2024 | 13872 | 0.200 |
Why?
|
| Aged | 12 | 2024 | 8214 | 0.200 |
Why?
|
| Terminology as Topic | 1 | 2023 | 42 | 0.200 |
Why?
|
| Dengue | 1 | 2024 | 107 | 0.200 |
Why?
|
| Arboviruses | 1 | 2022 | 8 | 0.190 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 306 | 0.190 |
Why?
|
| Multimedia | 3 | 2013 | 18 | 0.190 |
Why?
|
| Social Class | 1 | 2005 | 291 | 0.190 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2015 | 201 | 0.180 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 229 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 127 | 0.170 |
Why?
|
| Phylogeny | 2 | 2024 | 769 | 0.160 |
Why?
|
| Culicidae | 1 | 2020 | 26 | 0.160 |
Why?
|
| Slovenia | 1 | 2019 | 2 | 0.160 |
Why?
|
| Croatia | 1 | 2019 | 4 | 0.160 |
Why?
|
| Portugal | 1 | 2019 | 10 | 0.160 |
Why?
|
| France | 1 | 2019 | 23 | 0.160 |
Why?
|
| Turkey | 1 | 2019 | 23 | 0.160 |
Why?
|
| Cohort Studies | 8 | 2015 | 1759 | 0.150 |
Why?
|
| Genome, Viral | 1 | 2020 | 119 | 0.150 |
Why?
|
| Infant | 3 | 2021 | 1175 | 0.150 |
Why?
|
| Mexico | 1 | 2020 | 298 | 0.150 |
Why?
|
| Viral Load | 3 | 2015 | 348 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2018 | 63 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2018 | 863 | 0.140 |
Why?
|
| Forecasting | 1 | 2018 | 136 | 0.140 |
Why?
|
| Prevalence | 7 | 2021 | 1612 | 0.140 |
Why?
|
| BCG Vaccine | 1 | 2017 | 12 | 0.140 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2017 | 90 | 0.130 |
Why?
|
| Colombia | 3 | 2024 | 31 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 109 | 0.120 |
Why?
|
| Pancytopenia | 1 | 2015 | 3 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2016 | 90 | 0.120 |
Why?
|
| Sex Factors | 4 | 2018 | 1028 | 0.120 |
Why?
|
| Young Adult | 7 | 2024 | 5080 | 0.110 |
Why?
|
| Risk Factors | 8 | 2021 | 3994 | 0.110 |
Why?
|
| Child | 4 | 2024 | 3443 | 0.110 |
Why?
|
| Animals | 2 | 2023 | 16992 | 0.110 |
Why?
|
| Anemia | 1 | 2014 | 55 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 734 | 0.100 |
Why?
|
| Exercise | 1 | 2019 | 692 | 0.100 |
Why?
|
| Survival Rate | 3 | 2018 | 355 | 0.100 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2011 | 44 | 0.100 |
Why?
|
| Socioeconomic Factors | 4 | 2010 | 1234 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2019 | 590 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2014 | 925 | 0.100 |
Why?
|
| Mutation | 1 | 2017 | 1177 | 0.090 |
Why?
|
| Malaria, Vivax | 1 | 2012 | 5 | 0.090 |
Why?
|
| Quality of Life | 1 | 2017 | 616 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 1067 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 2 | 2022 | 74 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2024 | 1546 | 0.090 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2011 | 9 | 0.090 |
Why?
|
| Health Education | 1 | 2013 | 363 | 0.080 |
Why?
|
| Logistic Models | 3 | 2021 | 1009 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 638 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2017 | 568 | 0.080 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 486 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2853 | 0.070 |
Why?
|
| Computer-Assisted Instruction | 1 | 2008 | 26 | 0.070 |
Why?
|
| Age Factors | 3 | 2016 | 1154 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2018 | 2544 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1377 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 420 | 0.060 |
Why?
|
| Health Care Reform | 1 | 2005 | 36 | 0.060 |
Why?
|
| Leptospira | 1 | 2024 | 27 | 0.050 |
Why?
|
| Anti-HIV Agents | 2 | 2015 | 486 | 0.050 |
Why?
|
| Dengue Virus | 1 | 2024 | 96 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2008 | 236 | 0.050 |
Why?
|
| Orthobunyavirus | 1 | 2022 | 5 | 0.050 |
Why?
|
| Immune Sera | 1 | 2021 | 56 | 0.050 |
Why?
|
| Peru | 1 | 2021 | 41 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 512 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 67 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2017 | 1604 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2021 | 57 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2021 | 87 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2013 | 359 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1063 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 1078 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2001 | 258 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 97 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 719 | 0.040 |
Why?
|
| Comorbidity | 2 | 2014 | 737 | 0.030 |
Why?
|
| North America | 1 | 2018 | 85 | 0.030 |
Why?
|
| Psychophysiologic Disorders | 1 | 1997 | 8 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2021 | 666 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 861 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 89 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 38 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 69 | 0.030 |
Why?
|
| Unemployment | 1 | 2014 | 29 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 518 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1997 | 661 | 0.020 |
Why?
|
| Age Distribution | 2 | 2004 | 249 | 0.020 |
Why?
|
| Depression | 1 | 1997 | 863 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 400 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 195 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 233 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 485 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2008 | 81 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 368 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2008 | 259 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 374 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1857 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2006 | 74 | 0.010 |
Why?
|
| Health Behavior | 1 | 2010 | 575 | 0.010 |
Why?
|
| HIV | 1 | 2006 | 100 | 0.010 |
Why?
|
| Wasting Syndrome | 1 | 2004 | 5 | 0.010 |
Why?
|
| Needle Sharing | 1 | 2004 | 11 | 0.010 |
Why?
|
| Heroin Dependence | 1 | 2004 | 23 | 0.010 |
Why?
|
| Pneumonia, Bacterial | 1 | 2004 | 24 | 0.010 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 102 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 339 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2000 | 4 | 0.010 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2000 | 22 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 36 | 0.010 |
Why?
|
| Heterosexuality | 1 | 2000 | 97 | 0.010 |
Why?
|
| Sex Distribution | 1 | 1997 | 224 | 0.010 |
Why?
|
| Registries | 1 | 1997 | 437 | 0.010 |
Why?
|